FARN: Bexmarilimab reports 45% CR in HR-MDS
FARN says its Bexmarilimab delivered 45% CR in HR-MDS and that EUR 40M raised secures funding through 2027 milestones.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.